Citation:Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al 2009

From Cancer Guidelines Wiki

Citation


Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009 Dec 10;27(35):5931-7 Available from: http://www.ncbi.nlm.nih.gov/pubmed/19884549.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al 2009Optimal molecular profilingDr Albert Chetcuti BTech(Biotech) Hons, PhDcompleted
Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al 2009 2Optimal molecular profilingBen Lee-Batescompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:Molecular profiling of CRC|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Molecular profiling of CRC</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Molecular profiling of CRC|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Molecular profiling of CRC</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. Molecular pathology and biomarkers – implications for systemic therapy
  2. Optimal molecular profiling
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:Richman_SD,_Seymour_MT,_Chambers_P,_Elliott_F,_Daly_CL,_Meade_AM,_et_al_2009&oldid=149653"